4 October 2016
Two late stage CNS trials are in process by Amarex Clinical Research
Germantown, MD, USA - Amarex Clinical Research has initiated two late stage clinical trials in relation to Central Nervous System (CNS) indications. Amarex will be providing the full CRO services to conduct these trials in Schizophrenia in adults, which will be carried out across North America, Europe and Asia. The product under development has the potential to be a breakthrough drug for the indications under investigation.
The initiation of these trials is a testament to Amarex’s growth and capabilities to handle late stage trials, especially those of an international nature. Amarex will bring its broad experience in the CNS field to bear on these trials to bring them to fruition.
Amarex’s CEO, Kazem Kazempour said: “The clinical evidence indicates that these drugs has the potential to provide substantial improvement of a clinically significant endpoint over available therapies.”
Schizophrenia is a chronic and severe disorder that affects how a person thinks, feels, and acts. Although schizophrenia is not as common as other mental disorders, it can be very disabling. Approximately 7 or 8 individuals out of 1,000 will have schizophrenia in their lifetime.
About Amarex Clinical Research
Amarex is a global full service Contract Research Organization (CRO) that provides complete regulatory and clinical development services to take client’s products from laboratory proof of concept to achieving FDA approval of new or re-purposed medical products. Amarex creates regulatory approval plans for their clients and executes those plans through clinical research up to and including NDA, BLA, PMA, or 510(k) applications. Amarex works with all types of medical products in all therapeutic indications. The leadership team’s experience spans 30+ years of clinical research in Phase 1-4 trials, for over 300 projects, in more than 60 countries.
20201 Century Blvd, 4th Floor
Germantown, MD 20874